New FDA Approval for CML Patients

Asciminib (Scemblix) was recently approved for the following indications:

For patients with Philadelphia chromosome– positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have been previously treated with two or more tyrosine kinase inhibitors.

For patients with Ph+ CML in chronic phase with a T315I mutation

Here at Belong, we will continue to update you with new medical and research developments. If you are interested in clinical trial-related info or in participating in such a trial, you are invited to respond here or contact us in the “Find Clinical Trials” group.

Best of health,
The Clinical Trial Team

For more info:

This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service or treatment

Practical Ways to Manage Chemo Brain

Chemo brain, or cognitive difficulties caused by cancer treatment, can make daily tasks challenging. While…

Seeing Double? Let’s Dive into MS and Diplopia

Diplopia, or double vision, occurs when your brain receives mismatched signals from your eyes, leading…

Supplements and Cancer Treatments

Weighing the Pros and Cons. Many cancer patients turn to dietary supplements to support their…

Managing Depression with MS

Living with multiple sclerosis (MS) is more than just a physical challenge—it can also take…

Chemo and Back Pain – Understanding the Connection

Many cancer patients experience back pain during chemotherapy, a side effect that multiple factors can…

Vitamin D Reduces MS Activity

A recent study, the D-Lay MS trial, found that high-dose vitamin D3 significantly reduced disease…